Neuroinflammation and psychiatric illness

Journal of Neuroinflammation

Volumn 10, Issue , 2013, Pages

  Najjar, Souhel ^a,c   Pearlman, Daniel M ^b,c   Alper, Kenneth ^a   Najjar, Amanda ^a   Devinsky, Orrin ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Astrocyte; Bipolar disorder; Cytokines; Depression; Microglia; Neuroinflammation; Obsessive compulsive disorder; Oxidative stress; Psychoneuroimmunology; Schizophrenia

Indexed keywords

ACETYLSALICYLIC ACID; AMISULPRIDE; AUTOANTIBODY; AUTOANTIGEN; CELECOXIB; CIMICOXIB; CLOZAPINE; CYCLOOXYGENASE 2; CYTOKINE; DOCOSAHEXAENOIC ACID; FLUOXETINE; GLUTAMATE DECARBOXYLASE ANTIBODY; GLUTAMIC ACID; ICOSAPENTAENOIC ACID; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; KETAMINE; MINOCYCLINE; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PLACEBO; PREGNENOLONE; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN S100B; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SYNAPTIC ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN ANTIBODY REACTION; AUTOIMMUNE DISEASE; AUTOIMMUNE ENCEPHALITIDES; AUTOIMMUNITY; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BLOOD BRAIN BARRIER; DEPRESSION; DISEASE ASSOCIATION; DSM-IV; HEREDITY; HISTOPATHOLOGY; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; INNATE IMMUNITY; MACROGLIA; MAJOR DEPRESSION; MENTAL DISEASE; NEGATIVE SYNDROME; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROPSYCHIATRY; NONHUMAN; OBSESSIVE COMPULSIVE DISORDER; OLIGODENDROGLIA; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITIVE SYNDROME; REVIEW; SCHIZOPHRENIA; SINGLE DRUG DOSE; SOCIAL PSYCHOLOGY; SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

EID: 84875544837     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-10-43     Document Type: Review

References (268)

1. Kayser MS, Dalmau J. The emerging link between autoimmune disorders and neuropsychiatric disease. J Neuropsychiatry Clin Neurosci 2011, 23:90-97. 10.1176/appi.neuropsych.23.1.90, 3086677, 21304144.
2. Najjar S, Pearlman D, Zagzag D, Golfinos J, Devinsky O. Glutamic acid decarboxylase autoantibody syndrome presenting as schizophrenia. Neurologist 2012, 18:88-91. 10.1097/NRL.0b013e318247b87d, 22367838.
3. Graus F, Saiz A, Dalmau J. Antibodies and neuronal autoimmune disorders of the CNS. J Neurol 2010, 257:509-517. 10.1007/s00415-009-5431-9, 20035430.
4. Lennox BR, Coles AJ, Vincent A. Antibody-mediated encephalitis: a treatable cause of schizophrenia. Br J Psychiatry 2012, 200:92-94. 10.1192/bjp.bp.111.095042, 22297586.
5. Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, Coles AJ, Vincent A, Lennox BR. Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011, 258:686-688. 10.1007/s00415-010-5788-9, 3065649, 20972895.
6. Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld MR, Dalmau J. Autoimmune limbic encephalitis in 39 patients: immunophenotypes and outcomes. J Neurol Neurosurg Psychiatry 2007, 78:381-385. 2077770,2077770, 16980333.
7. Dale RC, Heyman I, Giovannoni G, Church AW. Incidence of anti-brain antibodies in children with obsessive-compulsive disorder. Br J Psychiatry 2005, 187:314-319. 10.1192/bjp.187.4.314, 16199788.
8. Kendler KS. The dappled nature of causes of psychiatric illness: replacing the organic-functional/hardware-software dichotomy with empirically based pluralism. Mol Psychiatry 2012, 17:377-388. 10.1038/mp.2011.182, 3312951, 22230881.
9. Keskin G, Sunter G, Midi I, Tuncer N. Neurosyphilis as a cause of cognitive decline and psychiatric symptoms at younger age. J Neuropsychiatry Clin Neurosci 2011, 23:E41-E42.
10. Leboyer M, Soreca I, Scott J, Frye M, Henry C, Tamouza R, Kupfer DJ. Can bipolar disorder be viewed as a multi-system inflammatory disease?. J Affect Disord 2012, 141:1-10. 10.1016/j.jad.2011.12.049, 3498820, 22497876.
11. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005, 36:1330-1340. 10.1161/01.STR.0000165928.19135.35, 15879342.
12. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 2008, 9:46-56. 10.1038/nrn2297, 2919277, 18073775.
13. Laske C, Zank M, Klein R, Stransky E, Batra A, Buchkremer G, Schott K. Autoantibody reactivity in serum of patients with major depression, schizophrenia and healthy controls. Psychiatry Res 2008, 158:83-86. 10.1016/j.psychres.2006.04.023, 18096244.
14. Eisenberger NI, Berkman ET, Inagaki TK, Rameson LT, Mashal NM, Irwin MR. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry 2010, 68:748-754. 10.1016/j.biopsych.2010.06.010, 3025604, 20719303.
15. Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162. 10.1038/npp.2011.205, 3238082, 21918508.
16. Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB. Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. Am J Psychiatry 2011, 168:1303-1310. 10.1176/appi.ajp.2011.11030516, 22193673.
17. McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depression: a literature review. CNS Spectr 2008, 13:501-510.
18. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry 2009, 66:407-414. 10.1016/j.biopsych.2009.03.015, 2885494, 19423079.
19. Raison CL, Miller AH. Is depression an inflammatory disorder?. Curr Psychiatry Rep 2011, 13:467-475. 10.1007/s11920-011-0232-0, 3285451, 21927805.
20. Raison CL, Miller AH. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Mol Psychiatry 2013, 18:15-37. 10.1038/mp.2012.2, 3532038, 22290120.
21. Steiner J, Bogerts B, Sarnyai Z, Walter M, Gos T, Bernstein HG, Myint AM. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: Potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry 2012, 13:482-492. 10.3109/15622975.2011.583941, 21707463.
22. Steiner J, Mawrin C, Ziegeler A, Bielau H, Ullrich O, Bernstein HG, Bogerts B. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 2006, 112:305-316. 10.1007/s00401-006-0090-8, 16783554.
23. Papakostas GI, Shelton RC, Kinrys G, Henry ME, Bakow BR, Lipkin SH, Pi B, Thurmond L, Bilello JA. Assessment of a multi-assay, serum-based biological diagnostic test for major depressive disorder: a pilot and replication study. Mol Psychiatry 2013, 18:332-339. 10.1038/mp.2011.166, 22158016.
24. Krishnan R. Unipolar depression in adults: epidemiology, pathogenesis, and neurobiology. In UpToDate. Edited by Basow DS 2013, Waltham, MA: UpToDate.
25. Stovall J. Bipolar disorder in adults: epidemiology and diagnosis. In UpToDate. Edited by Basow DS 2013, UpToDate: Waltham.
26. Fischer BA, Buchanan RW. Schizophrenia: epidemiology and pathogenesis. In UpToDate. Edited by Basow DS 2013, Waltham, MA: UpToDate.
27. Nestadt G, Samuels J, Riddle M, Bienvenu OJ, Liang KY, LaBuda M, Walkup J, Grados M, Hoehn-Saric R. A family study of obsessive-compulsive disorder. Arch Gen Psychiatry 2000, 57:358-363. 10.1001/archpsyc.57.4.358, 10768697.
28. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietilainen OP, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller HJ, Giegling I. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747. 3077530, 19571808.
29. Müller N, Schwarz MJ. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 2007, 12:988-1000. 10.1038/sj.mp.4002006, 17457312.
30. Galecki P, Florkowski A, Bienkiewics M, Szemraj J. Functional polymorphism of cyclooxygenase-2 gene (G-765C) in depressive patients. Neuropsychobiology 2010, 62:116-120. 10.1159/000317284, 20588070.
31. Levinson DF. The genetics of depression: a review. Biol Psychiatry 2006, 60:84-92. 10.1016/j.biopsych.2005.08.024, 16300747.
32. Zhai J, Cheng L, Dong J, Shen Q, Zhang Q, Chen M, Gao L, Chen X, Wang K, Deng X, Xu Z, Ji F, Liu C, Li J, Dong Q, Chen C. S100B gene polymorphisms predict prefrontal spatial function in both schizophrenia patients and healthy individuals. Schizophr Res 2012, 134:89-94. 10.1016/j.schres.2011.09.029, 22019077.
33. Zhai J, Zhang Q, Cheng L, Chen M, Wang K, Liu Y, Deng X, Chen X, Shen Q, Xu Z, Ji F, Liu C, Dong Q, Chen C, Li J. Risk variants in the S100B gene, associated with elevated S100B levels, are also associated with visuospatial disability of schizophrenia. Behav Brain Res 2011, 217:363-368. 10.1016/j.bbr.2010.11.004, 21070816.
34. Cappi C, Muniz RK, Sampaio AS, Cordeiro Q, Brentani H, Palacios SA, Marques AH, Vallada H, Miguel EC, Guilherme L, Hounie AG. Association study between functional polymorphisms in the TNF-alpha gene and obsessive-compulsive disorder. Arq Neuropsiquiatr 2012, 70:87-90. 10.1590/S0004-282X2012000200003, 22311210.
35. Miguel-Hidalgo JJ, Baucom C, Dilley G, Overholser JC, Meltzer HY, Stockmeier CA, Rajkowska G. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biol Psychiatry 2000, 48:861-873. 10.1016/S0006-3223(00)00999-9, 11063981.
36. Altshuler LL, Abulseoud OA, Foland Ross L, Bartzokis G, Chang S, Mintz J, Hellemann G, Vinters HV. Amygdala astrocyte reduction in subjects with major depressive disorder but not bipolar disorder. Bipolar Disord 2010, 12:541-549. 10.1111/j.1399-5618.2010.00838.x, 20712756.
37. Webster MJ, Knable MB, Johnston-Wilson N, Nagata K, Inagaki M, Yolken RH. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. Brain Behav Immun 2001, 15:388-400. 10.1006/brbi.2001.0646, 11782105.
38. Doyle C, Deakin JFW. Fewer astrocytes in frontal cortex in schizophrenia, depression and bipolar disorder. Schizophrenia Res 2002, 53:106.
39. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder, The Stanley Neuropathology Consortium. Mol Psychiatry 2000, 5:142-149. 10.1038/sj.mp.4000696, 10822341.
40. Gosselin RD, Gibney S, O'Malley D, Dinan TG, Cryan JF. Region specific decrease in glial fibrillary acidic protein immunoreactivity in the brain of a rat model of depression. Neuroscience 2009, 159:915-925. 10.1016/j.neuroscience.2008.10.018, 19000745.
41. Banasr M, Duman RS. Glial loss in the prefrontal cortex is sufficient to induce depressive-like behaviors. Biol Psychiatry 2008, 64:863-870. 10.1016/j.biopsych.2008.06.008, 2709733, 18639237.
42. Cotter D, Hudson L, Landau S. Evidence for orbitofrontal pathology in bipolar disorder and major depression, but not in schizophrenia. Bipolar Disord 2005, 7:358-369. 10.1111/j.1399-5618.2005.00230.x, 16026489.
43. Brauch RA, Adnan El-Masri M, Parker J, El-Mallakh RS. Glial cell number and neuron/glial cell ratios in postmortem brains of bipolar individuals. J Affect Disord 2006, 91:87-90. 10.1016/j.jad.2005.08.015, 16469390.
44. Cotter DR, Pariante CM, Everall IP. Glial cell abnormalities in major psychiatric disorders: the evidence and implications. Brain Res Bull 2001, 55:585-595. 10.1016/S0361-9230(01)00527-5, 11576755.
45. Cotter D, Mackay D, Landau S, Kerwin R, Everall I. Reduced glial cell density and neuronal size in the anterior cingulate cortex in major depressive disorder. Arch Gen Psychiatry 2001, 58:545-553. 10.1001/archpsyc.58.6.545, 11386983.
46. Bowley MP, Drevets WC, Ongür D, Price JL. Low glial numbers in the amygdala in major depressive disorder. Biol Psychiatry 2002, 52:404-412. 10.1016/S0006-3223(02)01404-X, 12242056.
47. Toro CT, Hallak JE, Dunham JS, Deakin JF. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neurosci Lett 2006, 404:276-281. 10.1016/j.neulet.2006.05.067, 16842914.
48. Rajkowska G, Miguel-Hidalgo JJ, Makkos Z, Meltzer H, Overholser J, Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophr Res 2002, 57:127-138. 10.1016/S0920-9964(02)00339-0, 12223243.
49. Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res 2008, 103:71-82. 10.1016/j.schres.2008.04.032, 18562176.
50. Damadzic R, Bigelow LB, Krimer LS, Goldenson DA, Saunders RC, Kleinman JE, Herman MM. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. Brain Res Bull 2001, 55:611-618. 10.1016/S0361-9230(01)00529-9, 11576757.
51. Benes FM, McSparren J, Bird ED, SanGiovanni JP, Vincent SL. Deficits in small interneurons in prefrontal and cingulate cortices of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 1991, 48:996-1001. 10.1001/archpsyc.1991.01810350036005, 1747023.
52. Müller N, Schwarz MJ. Immune system and schizophrenia. Curr Immunol Rev 2010, 6:213-220. 10.2174/157339510791823673, 2971548, 21057585.
53. Steiner J, Walter M, Gos T, Guillemin GJ, Bernstein HG, Sarnyai Z, Mawrin C, Brisch R, Bielau H, Meyer Zu Schwabedissen L, Bogerts B, Myint AM. Severe depression is associated with increased microglial quinolinic acid in subregions of the anterior cingulate gyrus: evidence for an immune-modulated glutamatergic neurotransmission?. J Neuroinflammation 2011, 8:94. 10.1186/1742-2094-8-94, 3177898, 21831269.
54. Vostrikov VM, Uranova NA, Orlovskaya DD. Deficit of perineuronal oligodendrocytes in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2007, 94:273-280. 10.1016/j.schres.2007.04.014, 17566708.
55. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets 2007, 6:219-233. 10.2174/187152707780619326, 2918806, 17511618.
56. Uranova NA, Vostrikov VM, Orlovskaya DD, Rachmanova VI. Oligodendroglial density in the prefrontal cortex in schizophrenia and mood disorders: a study from the Stanley Neuropathology Consortium. Schizophr Res 2004, 67:269-275. 10.1016/S0920-9964(03)00181-6, 14984887.
57. Uranova N. Damage and loss of oligodendrocytes are crucial in the pathogenesis of schizophrenia and mood disorders (findings form postmortem studies). Neuropsychopharmacology 2004, 29:S33.
58. Uranova NA, Orlovskaya DD, Vostrikov VM, Rachmanova VI. Decreased density of oligodendroglial satellites of pyramidal neurons in layer III in the prefrontal cortex in schizophrenia and mood disorders. Schizophr Res 2002, 53:107.
59. Vostrikov VM, Uranova NA, Rakhmanova VI, Orlovskaia DD. Lowered oligodendroglial cell density in the prefrontal cortex in schizophrenia. Zh Nevrol Psikhiatr Im S S Korsakova 2004, 104:47-51.
60. Uranova NA, Zimina IS, Vikhreva OV, Krukov NO, Rachmanova VI, Orlovskaya DD. Ultrastructural damage of capillaries in the neocortex in schizophrenia. World J Biol Psychiatry 2010, 11:567-578. 10.3109/15622970903414188, 20109113.
61. Hof PR, Haroutunian V, Friedrich VL, Byne W, Buitron C, Perl DP, Davis KL. Loss and altered spatial distribution of oligodendrocytes in the superior frontal gyrus in schizophrenia. Biol Psychiatry 2003, 53:1075-1085. 10.1016/S0006-3223(03)00237-3, 12814859.
62. Davis KL, Stewart DG, Friedman JI, Buchsbaum M, Harvey PD, Hof PR, Buxbaum J, Haroutunian V. White matter changes in schizophrenia: evidence for myelin-related dysfunction. Arch Gen Psychiatry 2003, 60:443-456. 10.1001/archpsyc.60.5.443, 12742865.
63. Flynn SW, Lang DJ, Mackay AL, Goghari V, Vavasour IM, Whittall KP, Smith GN, Arango V, Mann JJ, Dwork AJ, Falkai P, Honer WG. Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry 2003, 8:811-820. 10.1038/sj.mp.4001337, 12931208.
64. Uranova NA, Vostrikov VM, Vikhreva OV, Zimina IS, Kolomeets NS, Orlovskaya DD. The role of oligodendrocyte pathology in schizophrenia. Int J Neuropsychopharmacol 2007, 10:537-545. 10.1017/S1461145707007626, 17313698.
65. Byne W, Kidkardnee S, Tatusov A, Yiannoulos G, Buchsbaum MS, Haroutunian V. Schizophrenia-associated reduction of neuronal and oligodendrocyte numbers in the anterior principal thalamic nucleus. Schizophr Res 2006, 85:245-253. 10.1016/j.schres.2006.03.029, 16730162.
66. Hamidi M, Drevets WC, Price JL. Glial reduction in amygdala in major depressive disorder is due to oligodendrocytes. Biol Psychiatry 2004, 55:563-569. 10.1016/j.biopsych.2003.11.006, 15013824.
67. Bayer TA, Buslei R, Havas L, Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999, 271:126-128. 10.1016/S0304-3940(99)00545-5, 10477118.
68. Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, Bernstein HG, Bogerts B. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008, 42:151-157. 10.1016/j.jpsychires.2006.10.013, 17174336.
69. Rao JS, Harry GJ, Rapoport SI, Kim HW. Increased excitotoxicity and neuroinflammatory markers in postmortem frontal cortex from bipolar disorder patients. Mol Psychiatry 2010, 15:384-392. 10.1038/mp.2009.47, 2844920, 19488045.
70. Bernstein HG, Steiner J, Bogerts B. Glial cells in schizophrenia: pathophysiological significance and possible consequences for therapy. Expert Rev Neurother 2009, 9:1059-1071. 10.1586/ern.09.59, 19589054.
71. Chen SK, Tvrdik P, Peden E, Cho S, Wu S, Spangrude G, Capecchi MR. Hematopoietic origin of pathological grooming in Hoxb8 mutant mice. Cell 2010, 141:775-785. 10.1016/j.cell.2010.03.055, 2894573, 20510925.
72. Antony JM. Grooming and growing with microglia. Sci Signal 2010, 3:jc8. 10.1126/scisignal.3147jc8, 21062990.
73. Wonodi I, Stine OC, Sathyasaikumar KV, Roberts RC, Mitchell BD, Hong LE, Kajii Y, Thaker GK, Schwarcz R. Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry 2011, 68:665-674. 10.1001/archgenpsychiatry.2011.71, 21727251.
74. Raison CL, Lowry CA, Rook GA. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry 2010, 67:1211-1224. 10.1001/archgenpsychiatry.2010.161, 21135322.
75. Drexhage RC, Hoogenboezem TH, Versnel MA, Berghout A, Nolen WA, Drexhage HA. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav Immun 2011, 25:1206-1213. 10.1016/j.bbi.2011.03.013, 21443944.
76. Steiner J, Jacobs R, Panteli B, Brauner M, Schiltz K, Bahn S, Herberth M, Westphal S, Gos T, Walter M, Bernstein HG, Myint AM, Bogerts B. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur Arch Psychiatry Clin Neurosci 2010, 260:509-518. 10.1007/s00406-010-0098-x, 20107825.
77. Rotge JY, Aouizerate B, Tignol J, Bioulac B, Burbaud P, Guehl D. The glutamate-based genetic immune hypothesis in obsessive-compulsive disorder, An integrative approach from genes to symptoms. Neuroscience 2010, 165:408-417. 10.1016/j.neuroscience.2009.10.043, 19861150.
78. Yüksel C, Ongür D. Magnetic resonance spectroscopy studies of glutamate-related abnormalities in mood disorders. Biol Psychiatry 2010, 68:785-794. 10.1016/j.biopsych.2010.06.016, 2955841, 20728076.
79. Rao JS, Kellom M, Reese EA, Rapoport SI, Kim HW. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J Affect Disord 2012, 136:63-71. 10.1016/j.jad.2011.08.017, 3254216, 21925739.
80. Bauer D, Gupta D, Harotunian V, Meador-Woodruff JH, McCullumsmith RE. Abnormal expression of glutamate transporter and transporter interacting molecules in prefrontal cortex in elderly patients with schizophrenia. Schizophr Res 2008, 104:108-120. 10.1016/j.schres.2008.06.012, 2656372, 18678470.
81. Matute C, Melone M, Vallejo-Illarramendi A, Conti F. Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. 2005, 49:451-455.
82. Smith RE, Haroutunian V, Davis KL, Meador-Woodruff JH. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am J Psychiatry 2001, 158:1393-1399. 10.1176/appi.ajp.158.9.1393, 11532723.
83. McCullumsmith RE, Meador-Woodruff JH. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology 2002, 26:368-375. 10.1016/S0893-133X(01)00370-0, 11850151.
84. Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther 2011, 132:314-332. 10.1016/j.pharmthera.2011.09.006, 3205262, 21963369.
85. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009, 61:105-123. 10.1016/j.brainresrev.2009.05.005, 19481572.
86. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007, 62:1310-1316. 10.1016/j.biopsych.2007.03.017, 17574216.
87. Burbaeva G, Boksha IS, Turishcheva MS, Vorobyeva EA, Savushkina OK, Tereshkina EB. Glutamine synthetase and glutamate dehydrogenase in the prefrontal cortex of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:675-680. 10.1016/S0278-5846(03)00078-2, 12787856.
88. Bhattacharyya S, Khanna S, Chakrabarty K, Mahadevan A, Christopher R, Shankar SK. Anti-brain autoantibodies and altered excitatory neurotransmitters in obsessive-compulsive disorder. Neuropsychopharmacology 2009, 34:2489-2496. 10.1038/npp.2009.77, 19675532.
89. Sanacora G, Gueorguieva R, Epperson CN, Wu YT, Appel M, Rothman DL, Krystal JH, Mason GF. Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression. Arch Gen Psychiatry 2004, 61:705-713. 10.1001/archpsyc.61.7.705, 15237082.
90. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of 1H-MRS studies. Schizophr Bull 2013, 39:120-129. 10.1093/schbul/sbr069, 21746807.
91. Liu Y, Ho RC, Mak A. Interleukin (IL)-6, tumour necrosis factor alpha (TNF-alpha) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: a meta-analysis and meta-regression. J Affect Disord 2012, 139:230-239. 10.1016/j.jad.2011.08.003, 21872339.
92. Brietzke E, Stabellini R, Grassis-Oliveira R, Lafer B. Cytokines in bipolar disorder: recent findings, deleterious effects but promise for future therapeutics. CNS Spectr 2011, http://www.cnsspectrums.com/aspx/articledetail.aspx?articleid=3596.
93. Denys D, Fluitman S, Kavelaars A, Heijnen C, Westenberg H. Decreased TNF-alpha and NK activity in obsessive-compulsive disorder. Psychoneuroendocrinology 2004, 29:945-952. 10.1016/j.psyneuen.2003.08.008, 15177711.
94. Brambilla F, Perna G, Bellodi L, Arancio C, Bertani A, Perini G, Carraro C, Gava F. Plasma interleukin-1 beta and tumor necrosis factor concentrations in obsessive-compulsive disorders. Biol Psychiatry 1997, 42:976-981. 10.1016/S0006-3223(96)00495-7, 9386848.
95. Fluitman S, Denys D, Vulink N, Schutters S, Heijnen C, Westenberg H. Lipopolysaccharide-induced cytokine production in obsessive-compulsive disorder and generalized social anxiety disorder. Psychiatry Res 2010, 178:313-316. 10.1016/j.psychres.2009.05.008, 20452055.
96. Janelidze S, Mattei D, Westrin A, Traskman-Bendz L, Brundin L. Cytokine levels in the blood may distinguish suicide attempters from depressed patients. Brain Behav Immun 2011, 25:335-339. 10.1016/j.bbi.2010.10.010, 20951793.
97. Postal M, Costallat LT, Appenzeller S. Neuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management. CNS Drugs 2011, 25:721-736. 10.2165/11591670-000000000-00000, 21870886.
98. Kozora E, Hanly JG, Lapteva L, Filley CM. Cognitive dysfunction in systemic lupus erythematosus: past, present, and future. Arthritis Rheum 2008, 58:3286-3298. 10.1002/art.23991, 18975345.
99. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 2011, 77:179-189. 10.1212/WNL.0b013e318224afde, 3140073, 21747075.
100. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 2011, 10:63-74. 10.1016/S1474-4422(10)70253-2, 3158385, 21163445.
101. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, Dalmau J. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 2010, 9:776-785. 10.1016/S1474-4422(10)70137-X, 3086669, 20580615.
102. Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A, Martinez-Hernandez E, Wilson C, Jacobs D, Lai M, Walker RW, Graus F, Bataller L, Illa I, Markx S, Strauss KA, Peles E, Scherer SS, Dalmau J. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol 2011, 69:303-311. 10.1002/ana.22297, 3059252, 21387375.
103. Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Guzman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J. Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010, 9:67-76. 10.1016/S1474-4422(09)70324-2, 2824142, 19962348.
104. Lancaster E, Martinez-Hernandez E, Titulaer MJ, Boulos M, Weaver S, Antoine JC, Liebers E, Kornblum C, Bien CG, Honnorat J, Wong S, Xu J, Contractor A, Balice-Gordon R, Dalmau J. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology 2011, 77:1698-1701. 10.1212/WNL.0b013e3182364a44, 3208954, 22013185.
105. Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ, Galetta SL, Dichter M, Alavi A, Rosenfeld MR, Dalmau J. Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 2005, 128:1764-1777. 10.1093/brain/awh526, 1939694, 15888538.
106. Tofaris GK, Irani SR, Cheeran BJ, Baker IW, Cader ZM, Vincent A. Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis. Neurology 2012, 79:195-196. 10.1212/WNL.0b013e31825f0522, 3390544, 22744657.
107. Najjar S, Pearlman D, Najjar A, Ghiasian V, Zagzag D, Devinsky O. Extralimbic autoimmune encephalitis associated with glutamic acid decarboxylase antibodies: an underdiagnosed entity?. Epilepsy Behav 2011, 21:306-313. 10.1016/j.yebeh.2011.03.038, 21620774.
108. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 2013, 12:157-165. 10.1016/S1474-4422(12)70310-1, 23290630.
109. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 2008, 7:1091-1098. 10.1016/S1474-4422(08)70224-2, 2607118, 18851928.
110. Graus F, Boronat A, Xifro X, Boix M, Svigelj V, Garcia A, Palomino A, Sabater L, Alberch J, Saiz A. The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 2010, 74:857-859. 10.1212/WNL.0b013e3181d3e404, 20211911.
111. Lai M, Hughes EG, Peng X, Zhou L, Gleichman AJ, Shu H, Mata S, Kremens D, Vitaliani R, Geschwind MD, Bataller L, Kalb RG, Davis R, Graus F, Lynch DR, Balice-Gordon R, Dalmau J. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol 2009, 65:424-434. 10.1002/ana.21589, 2677127, 19338055.
112. Najjar S, Pearlman D, Devinsky O, Najjar A, Nadkarni S, Butler T, Zagzag D. Neuropsychiatric autoimmune encephalitis with negative VGKC-complex, NMDAR, and GAD autoantibodies: a case report and literature review, forthcoming. Cogn Behav Neurol in press.
113. Najjar S, Pearlman D, Zagzag D, Devinsky O. Spontaneously resolving seronegative autoimmune limbic encephalitis. Cogn Behav Neurol 2011, 24:99-105. 10.1097/WNN.0b013e3182248193, 21677575.
114. Gabilondo I, Saiz A, Galan L, Gonzalez V, Jadraque R, Sabater L, Sans A, Sempere A, Vela A, Villalobos F, Viñals M, Villoslada P, Graus F. Analysis of relapses in anti-NMDAR encephalitis. Neurology 2011, 77:996-999. 10.1212/WNL.0b013e31822cfc6b, 21865579.
115. Barry H, Hardiman O, Healy DG, Keogan M, Moroney J, Molnar PP, Cotter DR, Murphy KC. Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis. Br J Psychiatry 2011, 199:508-509. 10.1192/bjp.bp.111.092197, 21984802.
116. Dickerson F, Stallings C, Vaughan C, Origoni A, Khushalani S, Yolken R. Antibodies to the glutamate receptor in mania. Bipolar Disord 2012, 14:547-553. 10.1111/j.1399-5618.2012.01028.x, 22672262.
117. O'Loughlin K, Ruge P, McCauley M. Encephalitis and schizophrenia: a matter of words. Br J Psychiatry 2012, 201:74.
118. Parratt KL, Allan M, Lewis SJ, Dalmau J, Halmagyi GM, Spies JM. Acute psychiatric illness in a young woman: an unusual form of encephalitis. Med J Aust 2009, 191:284-286.
119. Suzuki Y, Kurita T, Sakurai K, Takeda Y, Koyama T. Case report of anti-NMDA receptor encephalitis suspected of schizophrenia. Seishin Shinkeigaku Zasshi 2009, 111:1479-1484.
120. Tsutsui K, Kanbayashi T, Tanaka K, Boku S, Ito W, Tokunaga J, Mori A, Hishikawa Y, Shimizu T, Nishino S. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012, 12:37. 10.1186/1471-244X-12-37, 3436772, 22569157.
121. Van Putten WK, Hachimi-Idrissi S, Jansen A, Van Gorp V, Huyghens L. Uncommon cause of psychotic behavior in a 9-year-old girl: a case report. Case Report Med 2012, 2012:358520.
122. Masdeu JC, Gonzalez-Pinto A, Matute C, Ruiz De Azua S, Palomino A, De Leon J, Berman KF, Dalmau J. Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. Am J Psychiatry 2012, 169:1120-1121.
123. Kirvan CA, Swedo SE, Kurahara D, Cunningham MW. Streptococcal mimicry and antibody-mediated cell signaling in the pathogenesis of Sydenham's chorea. Autoimmunity 2006, 39:21-29. 10.1080/08916930500484757, 16455579.
124. Swedo SE. Streptoccocal infection, Tourette syndrome, and OCD: is there a connection? Pandas: Horse or zebra?. Neurology 2010, 74:1397-1398.
125. Morer A, Lazaro L, Sabater L, Massana J, Castro J, Graus F. Antineuronal antibodies in a group of children with obsessive-compulsive disorder and Tourette syndrome. J Psychiatr Res 2008, 42:64-68. 10.1016/j.jpsychires.2006.09.010, 17113107.
126. Pavone P, Bianchini R, Parano E, Incorpora G, Rizzo R, Mazzone L, Trifiletti RR. Anti-brain antibodies in PANDAS versus uncomplicated streptococcal infection. Pediatr Neurol 2004, 30:107-110. 10.1016/S0887-8994(03)00413-2, 14984902.
127. Maina G, Albert U, Bogetto F, Borghese C, Berro AC, Mutani R, Rossi F, Vigliani MC. Anti-brain antibodies in adult patients with obsessive-compulsive disorder. J Affect Disord 2009, 116:192-200. 10.1016/j.jad.2008.11.019, 19138800.
128. Brimberg L, Benhar I, Mascaro-Blanco A, Alvarez K, Lotan D, Winter C, Klein J, Moses AE, Somnier FE, Leckman JF, Swedo SE, Cunningham MW, Joel D. Behavioral, pharmacological, and immunological abnormalities after streptococcal exposure: a novel rat model of Sydenham chorea and related neuropsychiatric disorders. Neuropsychopharmacology 2012, 37:2076-2087. 10.1038/npp.2012.56, 22534626.
129. Dale RC, Candler PM, Church AJ, Wait R, Pocock JM, Giovannoni G. Neuronal surface glycolytic enzymes are autoantigen targets in post-streptococcal autoimmune CNS disease. J Neuroimmunol 2006, 172:187-197. 10.1016/j.jneuroim.2005.10.014, 16356555.
130. Nicholson TR, Ferdinando S, Krishnaiah RB, Anhoury S, Lennox BR, Mataix-Cols D, Cleare A, Veale DM, Drummond LM, Fineberg NA, Church AJ, Giovannoni G, Heyman I. Prevalence of anti-basal ganglia antibodies in adult obsessive-compulsive disorder: cross-sectional study. Br J Psychiatry 2012, 200:381-386. 10.1192/bjp.bp.111.092007, 22282431.
131. Wu K, Hanna GL, Rosenberg DR, Arnold PD. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. Pharmacol Biochem Behav 2012, 100:726-735. 10.1016/j.pbb.2011.10.007, 3437220, 22024159.
132. Perlmutter SJ, Leitman SF, Garvey MA, Hamburger S, Feldman E, Leonard HL, Swedo SE. Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood. Lancet 1999, 354:1153-1158. 10.1016/S0140-6736(98)12297-3, 10513708.
133. Pereira A, Furlan FA. Astrocytes and human cognition: modeling information integration and modulation of neuronal activity. Prog Neurobiol 2010, 92:405-420. 10.1016/j.pneurobio.2010.07.001, 20633599.
134. Barres BA. The mystery and magic of glia: a perspective on their roles in health and disease. Neuron 2008, 60:430-440. 10.1016/j.neuron.2008.10.013, 18995817.
135. Verkhratsky A, Parpura V, Rodriguez JJ. Where the thoughts dwell: the physiology of neuronal-glial "diffuse neural net". Brain Res Rev 2011, 66:133-151. 10.1016/j.brainresrev.2010.05.002, 20546785.
136. Sofroniew MV. Molecular dissection of reactive astrogliosis and glial scar formation. Trends Neurosci 2009, 32:638-647. 10.1016/j.tins.2009.08.002, 2787735, 19782411.
137. Hamilton NB, Attwell D. Do astrocytes really exocytose neurotransmitters?. Nat Rev Neurosci 2010, 11:227-238. 10.1038/nrn2803, 20300101.
138. Rajkowska G. Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells. Biol Psychiatry 2000, 48:766-777. 10.1016/S0006-3223(00)00950-1, 11063973.
139. Coupland NJ, Ogilvie CJ, Hegadoren KM, Seres P, Hanstock CC, Allen PS. Decreased prefrontal Myo-inositol in major depressive disorder. Biol Psychiatry 2005, 57:1526-1534. 10.1016/j.biopsych.2005.02.027, 15953489.
140. Miguel-Hidalgo JJ, Overholser JC, Jurjus GJ, Meltzer HY, Dieter L, Konick L, Stockmeier CA, Rajkowska G. Vascular and extravascular immunoreactivity for intercellular adhesion molecule 1 in the orbitofrontal cortex of subjects with major depression: age-dependent changes. J Affect Disord 2011, 132:422-431. 10.1016/j.jad.2011.03.052, 3137705, 21536333.
141. Miguel-Hidalgo JJ, Wei JR, Andrew M, Overholser JC, Jurjus G, Stockmeier CA, Rajkowska G. Glia pathology in the prefrontal cortex in alcohol dependence with and without depressive symptoms. Biol Psychiatry 2002, 52:1121-1133. 10.1016/S0006-3223(02)01439-7, 3115671, 12488057.
142. Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, Uylings HB, Friedman L, Rajkowska G. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry 2004, 56:640-650. 10.1016/j.biopsych.2004.08.022, 2929806, 15522247.
143. Ongür D, Drevets WC, Price JL. Glial reduction in the subgenual prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998, 95:13290-13295. 10.1073/pnas.95.22.13290, 23786, 9789081.
144. Gittins RA, Harrison PJ. A morphometric study of glia and neurons in the anterior cingulate cortex in mood disorder. J Affect Disord 2011, 133:328-332. 10.1016/j.jad.2011.03.042, 21497910.
145. Cotter D, Mackay D, Beasley C, Kerwin R, Everall I. Reduced glial density and neuronal volume in major depressive disorder and schizophrenia in the anterior cingulate cortex [abstract]. Schizophrenia Res 2000, 41:106.
146. Si X, Miguel-Hidalgo JJ, Rajkowska G. GFAP expression is reduced in the dorsolateral prefrontal cortex in depression. In Society for Neuroscience; 2003 2003, Neuroscience Meeting Planne: New Orleans.
147. Legutko B, Mahajan G, Stockmeier CA, Rajkowska G. White matter astrocytes are reduced in depression. In Society for Neuroscience 2011, Neuroscience Meeting Planner: Washington, DC.
148. Edgar N, Sibille E. A putative functional role for oligodendrocytes in mood regulation. Transl Psychiatry 2012, 2:e109. 10.1038/tp.2012.34, 3365253, 22832953.
149. Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder. Biol Psychiatry 2001, 49:741-752. 10.1016/S0006-3223(01)01080-0, 11331082.
150. Cotter D, Mackay D, Chana G, Beasley C, Landau S, Everall IP. Reduced neuronal size and glial cell density in area 9 of the dorsolateral prefrontal cortex in subjects with major depressive disorder. Cereb Cortex 2002, 12:386-394. 10.1093/cercor/12.4.386, 11884354.
151. Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am J Psychiatry 2004, 161:882-888. 10.1176/appi.ajp.161.5.882, 15121654.
152. Konopaske GT, Dorph-Petersen KA, Sweet RA, Pierri JN, Zhang W, Sampson AR, Lewis DA. Effect of chronic antipsychotic exposure on astrocyte and oligodendrocyte numbers in macaque monkeys. Biol Psychiatry 2008, 63:759-765. 10.1016/j.biopsych.2007.08.018, 2386415, 17945195.
153. Selemon LD, Lidow MS, Goldman-Rakic PS. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biol Psychiatry 1999, 46:161-172. 10.1016/S0006-3223(99)00113-4, 10418690.
154. Steiner J, Bernstein HG, Bielau H, Farkas N, Winter J, Dobrowolny H, Brisch R, Gos T, Mawrin C, Myint AM, Bogerts B. S100B-immunopositive glia is elevated in paranoid as compared to residual schizophrenia: a morphometric study. J Psychiatr Res 2008, 42:868-876. 10.1016/j.jpsychires.2007.10.001, 18001771.
155. Carter CJ. eIF2B and oligodendrocyte survival: where nature and nurture meet in bipolar disorder and schizophrenia?. Schizophr Bull 2007, 33:1343-1353. 2779884, 17329232.
156. Hayashi Y, Nihonmatsu-Kikuchi N, Hisanaga S, Yu XJ, Tatebayashi Y. Neuropathological similarities and differences between schizophrenia and bipolar disorder: a flow cytometric postmortem brain study. PLoS One 2012, 7:e33019. 10.1371/journal.pone.0033019, 3305297, 22438888.
157. Uranova NA, Vikhreva OV, Rachmanova VI, Orlovskaya DD. Ultrastructural alterations of myelinated fibers and oligodendrocytes in the prefrontal cortex in schizophrenia: a postmortem morphometric study. Schizophr Res Treatment 2011, 2011:325789. 3420756, 22937264.
158. Torres-Platas SG, Hercher C, Davoli MA, Maussion G, Labonte B, Turecki G, Mechawar N. Astrocytic hypertrophy in anterior cingulate white matter of depressed suicides. Neuropsychopharmacology 2011, 36:2650-2658. 10.1038/npp.2011.154, 3230489, 21814185.
159. Pereira A, Furlan FA. On the role of synchrony for neuron-astrocyte interactions and perceptual conscious processing. J Biol Phys 2009, 35:465-480. 10.1007/s10867-009-9147-y, 2750741, 19669426.
160. Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiol Rev 2011, 91:461-553. 10.1152/physrev.00011.2010, 21527731.
161. Tremblay ME, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. The role of microglia in the healthy brain. J Neurosci 2011, 31:16064-16069. 10.1523/JNEUROSCI.4158-11.2011, 22072657.
162. Kaindl AM, Degos V, Peineau S, Gouadon E, Chhor V, Loron G, Le Charpentier T, Josserand J, Ali C, Vivien D, Collingridge GL, Lombet A, Issa L, Rene F, Loeffler JP, Kavelaars A, Verney C, Mantz J, Gressens P. Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain. Ann Neurol 2012, 72:536-549. 10.1002/ana.23626, 23109148.
163. Schwartz M, Shaked I, Fisher J, Mizrahi T, Schori H. Protective autoimmunity against the enemy within: fighting glutamate toxicity. Trends Neurosci 2003, 26:297-302. 10.1016/S0166-2236(03)00126-7, 12798598.
164. Pacheco R, Gallart T, Lluis C, Franco R. Role of glutamate on T-cell mediated immunity. J Neuroimmunol 2007, 185:9-19. 10.1016/j.jneuroim.2007.01.003, 17303252.
165. Najjar S, Pearlman D, Miller DC, Devinsky O. Refractory epilepsy associated with microglial activation. Neurologist 2011, 17:249-254. 10.1097/NRL.0b013e31822aad04, 21881466.
166. Schwartz M, Butovsky O, Bruck W, Hanisch UK. Microglial phenotype: is the commitment reversible?. Trends Neurosci 2006, 29:68-74. 10.1016/j.tins.2005.12.005, 16406093.
167. Wang F, Wu H, Xu S, Guo X, Yang J, Shen X. Macrophage migration inhibitory factor activates cyclooxygenase 2-prostaglandin E2 in cultured spinal microglia. Neurosci Res 2011, 71:210-218. 10.1016/j.neures.2011.07.1821, 21802455.
168. Zhang XY, Xiu MH, Song C, Chenda C, Wu GY, Haile CN, Kosten TA, Kosten TR. Increased serum S100B in never-medicated and medicated schizophrenic patients. J Psychiatr Res 2010, 44:1236-1240. 10.1016/j.jpsychires.2010.04.023, 20510426.
169. Kawasaki Y, Zhang L, Cheng JK, Ji RR. Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord. J Neurosci 2008, 28:5189-5194. 10.1523/JNEUROSCI.3338-07.2008, 2408767, 18480275.
170. Müller N, Schwarz MJ. The immunological basis of glutamatergic disturbance in schizophrenia: towards an integrated view. J Neural Transm Suppl 2007, 72:269-280. 10.1007/978-3-211-73574-9_33, 17982903.
171. Hestad KA, Tonseth S, Stoen CD, Ueland T, Aukrust P. Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy. J ECT 2003, 19:183-188. 10.1097/00124509-200312000-00002, 14657769.
172. Kubera M, Kenis G, Bosmans E, Zieba A, Dudek D, Nowak G, Maes M. Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol 2000, 52:237-241.
173. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671. 10.1016/j.biopsych.2011.04.013, 21641581.
174. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-808. 10.1016/j.biopsych.2007.09.024, 18005941.
175. Reale M, Patruno A, De Lutiis MA, Pesce M, Felaco M, Di Giannantonio M, Di Nicola M, Grilli A. Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls. BMC Neurosci 2011, 12:13. 10.1186/1471-2202-12-13, 3038147, 21266029.
176. Fluitman SB, Denys DA, Heijnen CJ, Westenberg HG. Disgust affects TNF-alpha, IL-6 and noradrenalin levels in patients with obsessive-compulsive disorder. Psychoneuroendocrinology 2010, 35:906-911. 10.1016/j.psyneuen.2009.12.005, 20044210.
177. Konuk N, Tekin IO, Ozturk U, Atik L, Atasoy N, Bektas S, Erdogan A. Plasma levels of tumor necrosis factor-alpha and interleukin-6 in obsessive compulsive disorder. Mediators Inflamm 2007, 2007:65704. 1847475, 17497035.
178. Monteleone P, Catapano F, Fabrazzo M, Tortorella A, Maj M. Decreased blood levels of tumor necrosis factor-alpha in patients with obsessive-compulsive disorder. Neuropsychobiology 1998, 37:182-185. 10.1159/000026500, 9648125.
179. Marazziti D, Presta S, Pfanner C, Gemignani A, Rossi A, Sbrana S, Rocchi V, Ambrogi F, Cassano GB. Immunological alterations in adult obsessive-compulsive disorder. Biol Psychiatry 1999, 46:810-814. 10.1016/S0006-3223(98)00371-0, 10494449.
180. Zai G, Arnold PD, Burroughs E, Richter MA, Kennedy JL. Tumor necrosis factor-alpha gene is not associated with obsessive-compulsive disorder. Psychiatr Genet 2006, 16:43. 10.1097/01.ypg.0000185026.12687.92, 16395130.
181. Rodríguez AD, González PA, García MJ, de la Rosa A, Vargas M, Marrero F. Circadian variations in proinflammatory cytokine concentrations in acute myocardial infarction. Rev Esp Cardiol 2003, 56:555-560.
182. Oliver JC, Bland LA, Oettinger CW, Arduino MJ, McAllister SK, Aguero SM, Favero MS. Cytokine kinetics in an in vitro whole blood model following an endotoxin challenge. Lymphokine Cytokine Res 1993, 12:115-120.
183. Le T, Leung L, Carroll WL, Schibler KR. Regulation of interleukin-10 gene expression: possible mechanisms accounting for its upregulation and for maturational differences in its expression by blood mononuclear cells. Blood 1997, 89:4112-4119.
184. Lee MC, Ting KK, Adams S, Brew BJ, Chung R, Guillemin GJ. Characterisation of the expression of NMDA receptors in human astrocytes. PLoS One 2010, 5:e14123. 10.1371/journal.pone.0014123, 2994931, 21152063.
185. Myint AM, Kim YK, Verkerk R, Scharpe S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord 2007, 98:143-151. 10.1016/j.jad.2006.07.013, 16952400.
186. Sanacora G, Treccani G, Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77. 10.1016/j.neuropharm.2011.07.036, 3205453, 21827775.
187. Saleh A, Schroeter M, Jonkmanns C, Hartung HP, Modder U, Jander S. In vivo MRI of brain inflammation in human ischaemic stroke. Brain 2004, 127:1670-1677. 10.1093/brain/awh191, 15128622.
188. Tilleux S, Hermans E. Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007, 85:2059-2070. 10.1002/jnr.21325, 17497670.
189. Helms HC, Madelung R, Waagepetersen HS, Nielsen CU, Brodin B. In vitro evidence for the brain glutamate efflux hypothesis: brain endothelial cells cocultured with astrocytes display a polarized brain-to-blood transport of glutamate. 2012, 60:882-893.
190. Leonard BE. The concept of depression as a dysfunction of the immune system. Curr Immunol Rev 2010, 6:205-212. 10.2174/157339510791823835, 3002174, 21170282.
191. Labrie V, Wong AH, Roder JC. Contributions of the D-serine pathway to schizophrenia. Neuropharmacology 2012, 62:1484-1503. 10.1016/j.neuropharm.2011.01.030, 21295046.
192. Gras G, Samah B, Hubert A, Leone C, Porcheray F, Rimaniol AC. EAAT expression by macrophages and microglia: still more questions than answers. Amino Acids 2012, 42:221-229. 10.1007/s00726-011-0866-6, 21373769.
193. Livingstone PD, Dickinson JA, Srinivasan J, Kew JN, Wonnacott S. Glutamate-dopamine crosstalk in the rat prefrontal cortex is modulated by Alpha7 nicotinic receptors and potentiated by PNU-120596. J Mol Neurosci 2010, 40:172-176. 10.1007/s12031-009-9232-5, 19688191.
194. Kondziella D, Brenner E, Eyjolfsson EM, Sonnewald U. How do glial-neuronal interactions fit into current neurotransmitter hypotheses of schizophrenia?. Neurochem Int 2007, 50:291-301. 10.1016/j.neuint.2006.09.006, 17084946.
195. Wu HQ, Pereira EF, Bruno JP, Pellicciari R, Albuquerque EX, Schwarcz R. The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci 2010, 40:204-210. 10.1007/s12031-009-9235-2, 19690987.
196. Steiner J, Bogerts B, Schroeter ML, Bernstein HG. S100B protein in neurodegenerative disorders. Clin Chem Lab Med 2011, 49:409-424.
197. Steiner J, Marquardt N, Pauls I, Schiltz K, Rahmoune H, Bahn S, Bogerts B, Schmidt RE, Jacobs R. Human CD8(+) T cells and NK cells express and secrete S100B upon stimulation. Brain Behav Immun 2011, 25:1233-1241. 10.1016/j.bbi.2011.03.015, 21447379.
198. Shanmugam N, Kim YS, Lanting L, Natarajan R. Regulation of cyclooxygenase-2 expression in monocytes by ligation of the receptor for advanced glycation end products. J Biol Chem 2003, 278:34834-34844. 10.1074/jbc.M302828200, 12837757.
199. Rothermundt M, Ohrmann P, Abel S, Siegmund A, Pedersen A, Ponath G, Suslow T, Peters M, Kaestner F, Heindel W, Arolt V, Pfleiderer B. Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:361-364. 10.1016/j.pnpbp.2006.09.013, 17081670.
200. Falcone T, Fazio V, Lee C, Simon B, Franco K, Marchi N, Janigro D. Serum S100B: a potential biomarker for suicidality in adolescents?. PLoS One 2010, 5:e11089. 10.1371/journal.pone.0011089, 2885416, 20559426.
201. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Serum markers support disease-specific glial pathology in major depression. J Affect Disord 2008, 111:271-280. 10.1016/j.jad.2008.03.005, 18430474.
202. Rothermundt M, Ahn JN, Jorgens S. S100B in schizophrenia: an update. Gen Physiol Biophys 2009, 28 Spec No Focus:F76-F81.
203. Schroeter ML, Abdul-Khaliq H, Krebs M, Diefenbacher A, Blasig IE. Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia-original research and meta-analysis. Psychiatry Res 2009, 167:66-72. 10.1016/j.psychres.2008.01.002, 19375171.
204. Rothermundt M, Missler U, Arolt V, Peters M, Leadbeater J, Wiesmann M, Rudolf S, Wandinger KP, Kirchner H. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 2001, 6:445-449. 10.1038/sj.mp.4000889, 11443531.
205. Suchankova P, Klang J, Cavanna C, Holm G, Nilsson S, Jonsson EG, Ekman A. Is the Gly82Ser polymorphism in the RAGE gene relevant to schizophrenia and the personality trait psychoticism?. J Psychiatry Neurosci 2012, 37:122-128. 10.1503/jpn.110024, 3297072, 22146151.
206. Scapagnini G, Davinelli S, Drago F, De Lorenzo A, Oriani G. Antioxidants as antidepressants: fact or fiction?. CNS Drugs 2012, 26:477-490. 10.2165/11633190-000000000-00000, 22668245.
207. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11:851-876.
208. Salim S, Chugh G, Asghar M. Inflammation in anxiety. Adv Protein Chem Struct Biol 2012, 88:1-25.
209. Anderson G, Berk M, Dodd S, Bechter K, Altamura AC, Dell'osso B, Kanba S, Monji A, Fatemi SH, Buckley P, Debnath M, Das UN, Meyer U, Müller N, Kanchanatawan B, Maes M. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:1-42.
210. Coughlin JM, Ishizuka K, Kano SI, Edwards JA, Seifuddin FT, Shimano MA, Daley EL. Marked reduction of soluble superoxide dismutase-1 (SOD1) in cerebrospinal fluid of patients with recent-onset schizophrenia. Mol Psychiatry 2012, 18:10-11.
211. Bombaci M, Grifantini R, Mora M, Reguzzi V, Petracca R, Meoni E, Balloni S, Zingaretti C, Falugi F, Manetti AG, Margarit I, Musser JM, Cardona F, Orefici G, Grandi G, Bensi G. Protein array profiling of tic patient sera reveals a broad range and enhanced immune response against Group A Streptococcus antigens. PLoS One 2009, 4:e6332. 10.1371/journal.pone.0006332, 2709431, 19623252.
212. Valerio A, Cardile A, Cozzi V, Bracale R, Tedesco L, Pisconti A, Palomba L, Cantoni O, Clementi E, Moncada S, Carruba MO, Nisoli E. TNF-alpha downregulates eNOS expression and mitochondrial biogenesis in fat and muscle of obese rodents. J Clin Invest 2006, 116:2791-2798. 1564431, 16981010.
213. Ott M, Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria, oxidative stress and cell death. Apoptosis 2007, 12:913-922. 10.1007/s10495-007-0756-2, 17453160.
214. Shalev H, Serlin Y, Friedman A. Breaching the blood-brain barrier as a gate to psychiatric disorder. Cardiovasc Psychiatry Neurol 2009, 2009:278531. 2775634, 19936105.
215. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006, 7:41-53. 10.1038/nrn1824, 16371949.
216. Bechter K, Reiber H, Herzog S, Fuchs D, Tumani H, Maxeiner HG. Cerebrospinal fluid analysis in affective and schizophrenic spectrum disorders: identification of subgroups with immune responses and blood-CSF barrier dysfunction. J Psychiatr Res 2010, 44:321-330. 10.1016/j.jpsychires.2009.08.008, 19796773.
217. Harris LW, Wayland M, Lan M, Ryan M, Giger T, Lockstone H, Wuethrich I, Mimmack M, Wang L, Kotter M, Craddock R, Bahn S. The cerebral microvasculature in schizophrenia: a laser capture microdissection study. PLoS One 2008, 3:e3964. 10.1371/journal.pone.0003964, 2597747, 19088852.
218. Lin JJ, Mula M, Hermann BP. Uncovering the neurobehavioural comorbidities of epilepsy over the lifespan. Lancet 2012, 380:1180-1192. 10.1016/S0140-6736(12)61455-X, 23021287.
219. Isingrini E, Belzung C, Freslon JL, Machet MC, Camus V. Fluoxetine effect on aortic nitric oxide-dependent vasorelaxation in the unpredictable chronic mild stress model of depression in mice. Psychosom Med 2012, 74:63-72. 10.1097/PSY.0b013e31823a43e0, 22210237.
220. Zhang XY, Zhou DF, Cao LY, Zhang PY, Wu GY, Shen YC. The effect of risperidone treatment on superoxide dismutase in schizophrenia. J Clin Psychopharmacol 2003, 23:128-131. 10.1097/00004714-200304000-00004, 12640213.
221. Lavoie KL, Pelletier R, Arsenault A, Dupuis J, Bacon SL. Association between clinical depression and endothelial function measured by forearm hyperemic reactivity. Psychosom Med 2010, 72:20-26. 10.1097/PSY.0b013e3181c2d6b8, 19875632.
222. Chrapko W, Jurasz P, Radomski MW, Archer SL, Newman SC, Baker G, Lara N, Le Melledo JM. Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology 2006, 31:1286-1293.
223. Chrapko WE, Jurasz P, Radomski MW, Lara N, Archer SL, Le Melledo JM. Decreased platelet nitric oxide synthase activity and plasma nitric oxide metabolites in major depressive disorder. Biol Psychiatry 2004, 56:129-134. 10.1016/j.biopsych.2004.03.003, 15231445.
224. Stuehr DJ, Santolini J, Wang ZQ, Wei CC, Adak S. Update on mechanism and catalytic regulation in the NO synthases. J Biol Chem 2004, 279:36167-36170. 10.1074/jbc.R400017200, 15133020.
225. Chen W, Druhan LJ, Chen CA, Hemann C, Chen YR, Berka V, Tsai AL, Zweier JL. Peroxynitrite induces destruction of the tetrahydrobiopterin and heme in endothelial nitric oxide synthase: transition from reversible to irreversible enzyme inhibition. Biochemistry 2010, 49:3129-3137. 10.1021/bi9016632, 2851177, 20184376.
226. Chen CA, Wang TY, Varadharaj S, Reyes LA, Hemann C, Talukder MA, Chen YR, Druhan LJ, Zweier JL. S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010, 468:1115-1118. 10.1038/nature09599, 3370391, 21179168.
227. Szabo C, Ischiropoulos H, Radi R. Peroxynitrite: biochemistry, pathophysiology and development of therapeutics. Nat Rev Drug Discov 2007, 6:662-680. 10.1038/nrd2222, 17667957.
228. Papakostas GI, Shelton RC, Zajecka JM, Etemad B, Rickels K, Clain A, Baer L, Dalton ED, Sacco GR, Schoenfeld D, Pencina M, Meisner A, Bottiglieri T, Nelson E, Mischoulon D, Alpert JE, Barbee JG, Zisook S, Fava M. L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials. Am J Psychiatry 2012, 169:1267-1274. 10.1176/appi.ajp.2012.11071114, 23212058.
229. Antoniades C, Shirodaria C, Warrick N, Cai S, de Bono J, Lee J, Leeson P, Neubauer S, Ratnatunga C, Pillai R, Refsum H, Channon KM. 5-methyltetrahydrofolate rapidly improves endothelial function and decreases superoxide production in human vessels: effects on vascular tetrahydrobiopterin availability and endothelial nitric oxide synthase coupling. Circulation 2006, 114:1193-1201. 10.1161/CIRCULATIONAHA.106.612325, 16940192.
230. Masano T, Kawashima S, Toh R, Satomi-Kobayashi S, Shinohara M, Takaya T, Sasaki N, Takeda M, Tawa H, Yamashita T, Yokoyama M, Hirata K. Beneficial effects of exogenous tetrahydrobiopterin on left ventricular remodeling after myocardial infarction in rats: the possible role of oxidative stress caused by uncoupled endothelial nitric oxide synthase. Circ J 2008, 72:1512-1519. 10.1253/circj.CJ-08-0072, 18724032.
231. Alp NJ, Channon KM. Regulation of endothelial nitric oxide synthase by tetrahydrobiopterin in vascular disease. Arterioscler Thromb Vasc Biol 2004, 24:413-420. 10.1161/01.ATV.0000110785.96039.f6, 14656731.
232. Szymanski S, Ashtari M, Zito J, Degreef G, Bogerts B, Lieberman J. Gadolinium-DTPA enhanced gradient echo magnetic resonance scans in first episode of psychosis and chronic schizophrenic patients. Psychiatry Res 1991, 40:203-207. 10.1016/0925-4927(91)90011-E, 1780393.
233. Butler T, Weisholtz D, Isenberg N, Harding E, Epstein J, Stern E, Silbersweig D. Neuroimaging of frontal-limbic dysfunction in schizophrenia and epilepsy-related psychosis: toward a convergent neurobiology. Epilepsy Behav 2012, 23:113-122. 10.1016/j.yebeh.2011.11.004, 3339259, 22209327.
234. Butler T, Maoz A, Vallabhajosula S, Moeller J, Ichise M, Paresh K, Pervez F, Friedman D, Goldsmith S, Najjar S, Osborne J, Solnes L, Wang X, French J, Thesen T, Devinsky O, Kuzniecky R, Stern E, Silbersweig D. Imaging inflammation in a patient with epilepsy associated with antibodies to glutamic acid decarboxylase [abstract]. Am Epilepsy Society Abstracts, Volume 2 2011, 191. Baltimore: American Epilepsy Society.
235. van Berckel BN, Bossong MG, Boellaard R, Kloet R, Schuitemaker A, Caspers E, Luurtsema G, Windhorst AD, Cahn W, Lammertsma AA, Kahn RS. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008, 64:820-822. 10.1016/j.biopsych.2008.04.025, 18534557.
236. Doorduin J, de Vries EF, Willemsen AT, de Groot JC, Dierckx RA, Klein HC. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009, 50:1801-1807. 10.2967/jnumed.109.066647, 19837763.
237. Takano A, Arakawa R, Ito H, Tateno A, Takahashi H, Matsumoto R, Okubo Y, Suhara T. Peripheral benzodiazepine receptors in patients with chronic schizophrenia: a PET study with [11C]DAA1106. Int J Neuropsychopharmacol 2010, 13:943-950. 10.1017/S1461145710000313, 20350336.
238. Müller N, Schwarz MJ, Dehning S, Douhe A, Cerovecki A, Goldstein-Muller B, Spellmann I, Hetzel G, Maino K, Kleindienst N, Möller HJ, Arolt V, Riedel M. The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry 2006, 11:680-684. 10.1038/sj.mp.4001805, 16491133.
239. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009, 26:607-611. 10.1002/da.20589, 19496103.
240. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol 2006, 21:227-231. 10.1097/00004850-200607000-00005, 16687994.
241. Uher R, Carver S, Power RA, Mors O, Maier W, Rietschel M, Hauser J, Dernovsek MZ, Henigsberg N, Souery D, Placentino A, Farmer A, McGuffin P. Non-steroidal anti-inflammatory drugs and efficacy of antidepressants in major depressive disorder. Psychol Med 2012, 42:2027-2035. 10.1017/S0033291712000190, 22391106.
242. Müller N, Riedel M, Scheppach C, Brandstatter B, Sokullu S, Krampe K, Ulmschneider M, Engel RR, Moller HJ, Schwarz MJ. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia. Am J Psychiatry 2002, 159:1029-1034. 10.1176/appi.ajp.159.6.1029, 12042193.
243. Müller N, Riedel M, Schwarz MJ, Engel RR. Clinical effects of COX-2 inhibitors on cognition in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2005, 255:149-151. 10.1007/s00406-004-0548-4, 15549344.
244. Müller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M, Moller HJ, Klauss V, Schwarz MJ, Riedel M. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res 2010, 121:118-124. 10.1016/j.schres.2010.04.015, 20570110.
245. Sayyah M, Boostani H, Pakseresht S, Malayeri A. A preliminary randomized double-blind clinical trial on the efficacy of celecoxib as an adjunct in the treatment of obsessive-compulsive disorder. Psychiatry Res 2011, 189:403-406. 10.1016/j.psychres.2011.01.019, 21329988.
246. Sublette ME, Ellis SP, Geant AL, Mann JJ. Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry 2011, 72:1577-1584. 10.4088/JCP.10m06634, 3534764, 21939614.
247. Bloch MH, Hannestad J. Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 2012, 17:1272-1282. 10.1038/mp.2011.100, 21931319.
248. Keller WR, Kum LM, Wehring HJ, Koola MM, Buchanan RW, Kelly DL. A review of anti-inflammatory agents for symptoms of schizophrenia. J Psychopharmacol
249. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci USA 2011, 108:9262-9267. 10.1073/pnas.1104836108, 3107316, 21518864.
250. Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. Am J Psychiatry 2012, 169:1065-1072. 10.1176/appi.ajp.2012.11091325, 23032386.
251. Shelton RC. Does concomitant use of NSAIDs reduce the effectiveness of antidepressants?. Am J Psychiatry 2012, 169:1012-1015. 10.1176/appi.ajp.2012.12070924, 23032377.
252. Martinez-Gras I, Perez-Nievas BG, Garcia-Bueno B, Madrigal JL, Andres-Esteban E, Rodriguez-Jimenez R, Hoenicka J, Palomo T, Rubio G, Leza JC. The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr Res 2011, 128:15-22. 10.1016/j.schres.2011.01.018, 21334179.
253. Garcia-Bueno B, Perez-Nievas BG, Leza JC. Is there a role for the nuclear receptor PPARgamma in neuropsychiatric diseases?. Int J Neuropsychopharmacol 2010, 13:1411-1429. 10.1017/S1461145710000970, 20800014.
254. Meyer U. Anti-inflammatory signaling in schizophrenia. Brain Behav Immun 2011, 25:1507-1518. 10.1016/j.bbi.2011.05.014, 21664451.
255. Ramer R, Heinemann K, Merkord J, Rohde H, Salamon A, Linnebacher M, Hinz B. COX-2 and PPAR-gamma confer cannabidiol-induced apoptosis of human lung cancer cells. Mol Cancer Ther 2013, 12:69-82. 10.1158/1535-7163.MCT-12-0335, 23220503.
256. Henry CJ, Huang Y, Wynne A, Hanke M, Himler J, Bailey MT, Sheridan JF, Godbout JP. Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. J Neuroinflammation 2008, 5:15. 10.1186/1742-2094-5-15, 2412862, 18477398.
257. Sarris J, Mischoulon D, Schweitzer I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 2012, 73:81-86. 10.4088/JCP.10r06710, 21903025.
258. Amminger GP, Schafer MR, Papageorgiou K, Klier CM, Cotton SM, Harrigan SM, Mackinnon A, McGorry PD, Berger GE. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial. Arch Gen Psychiatry 2010, 67:146-154. 10.1001/archgenpsychiatry.2009.192, 20124114.
259. Fusar-Poli P, Berger G. Eicosapentaenoic acid interventions in schizophrenia: meta-analysis of randomized, placebo-controlled studies. J Clin Psychopharmacol 2012, 32:179-185. 10.1097/JCP.0b013e318248b7bb, 22367656.
260. Zorumski CF, Paul SM, Izumi Y, Covey DF, Mennerick S. Neurosteroids, stress and depression: Potential therapeutic opportunities. Neurosci Biobehav Rev 2013, 37:109-122. 10.1016/j.neubiorev.2012.10.005, 23085210.
261. Uhde TW, Singareddy R. Biological Research in Anxiety Disorders. Psychiatry as a Neuroscience 2002, 237-286. Chichester: John Wiley & Sons, Ltd, Juan Jose L-I, Wolfgang G, Mario M, Norman S.
262. Gibson SA, Korado Z, Shelton RC. Oxidative stress and glutathione response in tissue cultures from persons with major depression. J Psychiatr Res 2012, 46:1326-1332. 10.1016/j.jpsychires.2012.06.008, 22841833.
263. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC. Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. 2008, 23:87-94.
264. Levine J, Cholestoy A, Zimmerman J. Possible antidepressant effect of minocycline. 1996, 153:582.
265. Levkovitz Y, Mendlovich S, Riwkes S, Braw Y, Levkovitch-Verbin H, Gal G, Fennig S, Treves I, Kron S. A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizohprenia. J Clin Psychiatry 2010, 71:138-149. 10.4088/JCP.08m04666yel, 19895780.
266. Miyaoka T, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Possible antipsychotic effect of minocycline in patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2007, 31:304-307. 10.1016/j.pnpbp.2006.08.013, 17030375.
267. Miyaoka J, Yasukawa R, Yasuda H, Hayashida M, Inagaki T, Horiguchi J. Minocycline as adjunctive therapy for schizophrenia: an open-label study. 2008, 31:287-292.
268. Rodriguez CI, Bender J, Marcus SM, Snape M, Rynn M, Simpson HB. Minocycline augmentation of pharmacotherapy in obsessive-compulsive disorder: an open-label trial. 2010, 71:1247-1249.